The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 741 Metabolic Health articles
New research presented at Digestive Disease Week 2026 suggests a minimally invasive 'gut reset' procedure could help patients maintain weight loss after discontinuing GLP-1 medications like Ozempic and Wegovy. The findings address a major challenge in obesity treatment: weight regain after stopping therapy.
Tight insurance restrictions on obesity drugs are turning doctors into financial advisors and patients into strategists. With coverage limits on Zepbound favoring Wegovy, many are pivoting to compounded alternatives at $300/month versus $450 for brand names. Explore the real challenges and solutions from experts and patients.
Amazon One Medical has launched a new weight management program featuring GLP-1 medications, providing transparent pricing and dedicated primary care oversight. With GLP-1 pills starting at $25 per month with insurance or $149 cash-pay, and injectables at $299, this initiative addresses key barriers like cost. Available nationwide with rapid delivery, it builds on Amazon's growing healthcare ecosystem.
For Meghan Lena, losing coverage for Zepbound felt devastating after losing 50 pounds. Now, GoodRx reports 12 million people will lose access to Zepbound and Wegovy from 2025-2026 due to insurance changes. Patients are pivoting to alternatives amid rising restrictions and costs.
The European grocery sector gained momentum in 2026 with private labels, adjacent categories, M&A, and AI creating opportunities despite margin pressures. McKinsey's report, partnered with EuroCommerce and Europanel, details 3.4% sales growth in 2025 and eight key trends defining the future. CEOs expect stability as volume growth returns modestly.
Pfizer's GLP-1 weight management drug Xianweiying is available for pre-order on JD.com in China, intensifying rivalry in a market projected to reach billions. Priced at 489 yuan ($72) for a 1.2 ml injector pen with shipping from April 27, it challenges leaders like Novo Nordisk's Wegovy and Innovent's Xinermei. This move bolsters Pfizer's position via licensing from Sciwind.
The mantra 'once an accident, twice a coincidence, three times a trend' fuels bad journalism—and worse, risky medicine. A New Yorker investigation exposes clinics pushing unproven peptides for healing and longevity, backed by RFK Jr. While semaglutide proves the exception, most lack evidence and pose real harms.
Started GLP-1s for weight loss or blood sugar control but seeing no results? New research in Genome Medicine reveals that 10% of people carry PAM gene variants linked to weaker responses. Experts explain genetics, common pitfalls, testing, and effective alternatives to help you succeed.
Christina Aguilera turned heads at the Breakthrough Prize Ceremony, appearing 'thinner than ever' in a plunging black leather dress that highlighted her minuscule waist. Amid ongoing Ozempic rumors, fans commented 'Ozempic strikes again' on her super-slim frame. This sighting reignites discussions on celebrity weight loss and GLP-1 medications.
